XML 54 R10.htm IDEA: XBRL DOCUMENT

Inventory

3 Months Ended

Mar. 31, 2015

(4)

Inventory

After approval of Vascepa on July 26, 2012 by the FDA, the Company began capitalizing its purchases of saleable inventory of Vascepa from suppliers that have been qualified by the FDA. Inventories consist of the following (in thousands):


	March 31, 2015		December 31, 2014
Raw materials	$	8,600	$	5,225
Work in process		4,934		4,757
Finished goods		2,649		3,751

Total inventory	$	16,183	$	13,733

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details